Trevi Therapeutics, Inc. (TRVI)

NASDAQ • Healthcare

$17.26

+$0.2 (+1.2%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$16.8 - $17.31

Avg. Volume (3M)1.4M

Market Cap$2.4B

52 Week Range

$6.93$20.22

Next EarningsIn 69 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$51.1M

EPS (TTM)

-$0.34

ROA (TTM)

-15.46%

Current Ratio

37.28

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+10.0%Q3 2025-$0.09

+20.0%Q4 2025-$0.08

+40.0%Q1 2026-$0.06

-28.6%Q2 2026-$0.09

-0.5%Q3 2026-$0.11

Nov 12

in 69 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -0.5%

Trevi Therapeutics’ preliminary results for the second fiscal quarter of 2026 showed a wider year-over-year loss, with EPS coming in in line with consensus; the company reported the quarter ended June 30, 2026 on August 6, 2026. EPS was -$0.110 versus the -$0.109 estimate (difference -$0.001, in line), and was down ~22% from -$0.090 a year ago. Net income was -$17.8 million, down ~45% from -$12.3 million a year ago, while operating income stood at -$20.5 million. Cash burn remained evident, with negative operating cash flow of -$17.4 million during the quarter. Consensus for the next period calls for EPS of -$0.130.

View full earnings history

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing Haduvio for neurologically mediated conditions. The company is an early-stage healthcare business rather than a commercial drug seller, with its work centered on a single oral therapy candidate from its base in New Haven, Connecticut.

Name

Trevi Therapeutics, Inc.

CEO

Jennifer L. Good

Website

www.trevitherapeutics.com

Industry

Healthcare

Year Founded

2011

Employees

Today's Snapshot

AI-generated

TRVI closed 1.2% above yesterday's close, outperforming a weaker sector. Volume was about two-thirds of its usual level.

Trading Volume

Below 10d avg (1.4M)

831.6K

vs S&P 500 Today

Outperforming Market

+1.59%

Updated: September 4, 2026 at 20:03 UTC

Technical Indicators

2 Buy2 Neutral4 Sell

TRVI reflects short-term weakness with the current price about $17.26 and negative momentum reinforced by a slightly negative MACD and declining short EMAs, while RSI and several oscillators remain neutral to mildly bearish. Trend strength is modest with ADX near 20, suggesting limited directional conviction, and volatility is elevated relative to price with ATR near 4.7%. On-balance volume shows selling pressure, even though longer-term averages sit below the market and may offer structural support. Technical takeaway: Sell — short-term selling pressure and weak momentum dominate despite longer-term support.

All signals